1-14 of 14
Jun Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P1-06-17: Inhibition of oncogenic PTK6 kinase enhances immune response against triple negative breast cancer via EMT reversal

Free
Hanna Irie, Ibuki Harada, Criseyda Martinez, Koichi Ito, Eunjee Lee, Jun Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-06-17.
https://doi.org/10.1158/1557-3265.SABCS24-P1-06-17
Published: 13 June 2025
View articletitled, Abstract P1-06-17: Inhibition of oncogenic PTK6 kinase enhances immune response against triple negative breast cancer via EMT reversal
Journal Articles

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Available to Purchase
Jonathan Chou, Troy M. Robinson, Emily A. Egusa, Roshan Lodha, Meng Zhang, Michelle Badura, Mane Mikayelyan, Henry M. Delavan, Jason Swinderman, Chris Wilson, Jun Zhu, Rajdeep Das, Minh Nguyen, Andrea Loehr, Tony Golsorkhi, Andrew Simmons, Wassim Abida, Arul M. Chinnaiyan, Michelle R. Arkin, Eric J. Small, David A. Quigley, Lixing Yang, Minkyu Kim, Alan Ashworth, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5445–5458.
https://doi.org/10.1158/1078-0432.CCR-23-3785
Published: 02 December 2024
View articletitled, Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Open the PDF for Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract PR008: Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy

Free
Kevin Chang, Henry M. Delavan, Jun Zhu, Corynn Kasap, Elizabeth Yip, Roshan Lodha, Sheng-You Liao, Sima Porten, Terence Friedlander, Vadim Koshkin, Felix Feng, Arun Wiita, John Lee, Carissa E. Chu, Jonathan Chou
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): PR008.
https://doi.org/10.1158/1557-3265.BLADDER24-PR008
Published: 17 May 2024
View articletitled, Abstract PR008: Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy
Journal Articles

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Available to Purchase
Yuqin Song, Zhengming Jin, Zhi-Ming Li, Yanyan Liu, Lanfang Li, Chuan He, Hang Su, Hui Zhou, Kunyan Li, Siguo Hao, Xuelan Zuo, Jianyuan Wu, Dengju Li, Meng Wu, Xiuhua Sun, Junyuan Qi, Zhen Cai, Zengjun Li, Yijing Li, Yanhua Huang, Jie Shen, Zhenyu Xiao, Jun Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1248–1255.
https://doi.org/10.1158/1078-0432.CCR-23-2582
Published: 01 April 2024
View articletitled, Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Open the PDF for Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study in another window
Includes: Supplementary data
Journal Articles

Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

Available to Purchase
Shalini Chopra, Kai Trepka, Sasank Sakhamuri, Alberto Carretero-González, Jun Zhu, Emily Egusa, Jie Zhou, Kevin Leung, Ning Zhao, Nima Hooshdaran, Felix Y. Feng, James A. Wells, Jonathan Chou, Michael J. Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1232–1242.
https://doi.org/10.1158/1078-0432.CCR-22-1973
Published: 03 April 2023
View articletitled, Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Open the PDF for Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease

Available to Purchase
Ning Zhao, Shalini Chopra, Kai Trepka, Yung-Hua Wang, Sasank Sakhamuri, Nima Hooshdaran, Hyunjung Kim, Jie Zhou, Shion A. Lim, Kevin K. Leung, Emily A. Egusa, Jun Zhu, Li Zhang, Adam Foye, Renuka Sriram, Emily Chan, Youngho Seo, Felix Y. Feng, Eric J. Small, Jonathan Chou, James A. Wells, Rahul Aggarwal, Michael J. Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3066–3075.
https://doi.org/10.1158/1078-0432.CCR-21-3858
Published: 15 July 2022
View articletitled, CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Open the PDF for CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease in another window
Includes: Supplementary data
Journal Articles

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Open Access
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1147–1156.
https://doi.org/10.1158/1078-0432.CCR-21-2023
Published: 15 March 2022
View articletitled, Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Open the PDF for Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis in another window
Includes: Supplementary data
Journal Articles

Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Available to Purchase
Carissa E. Chu, Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura, Jun Zhu, Vadim S. Koshkin, Bradley A. Stohr, Maxwell V. Meng, Raj S. Pruthi, Terence W. Friedlander, Yair Lotan, Peter C. Black, Sima P. Porten, Felix Y. Feng, Jonathan Chou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5123–5130.
https://doi.org/10.1158/1078-0432.CCR-20-4175
Published: 15 September 2021
View articletitled, Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Open the PDF for Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin in another window
Includes: Supplementary data
Journal Articles

Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing

Available to Purchase
Li Wang, John P. Sfakianos, Kristin G. Beaumont, Guray Akturk, Amir Horowitz, Robert P. Sebra, Adam M. Farkas, Sacha Gnjatic, Austin Hake, Sudeh Izadmehr, Peter Wiklund, William K. Oh, Peter M. Szabo, Megan Wind-Rotolo, Keziban Unsal-Kacmaz, Xin Yao, Eric Schadt, Padmanee Sharma, Nina Bhardwaj, Jun Zhu, Matthew D. Galsky
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4287–4300.
https://doi.org/10.1158/1078-0432.CCR-20-4574
Published: 01 August 2021
View articletitled, Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing
Open the PDF for Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing in another window
Includes: Supplementary data
Journal Articles

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Free
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei, Jun Zhu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4216–4224.
https://doi.org/10.1158/1078-0432.CCR-19-3703
Published: 14 August 2020
View articletitled, Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Open the PDF for Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase in another window
Includes: Supplementary data
Journal Articles

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Free
Yuqin Song, Jianqiu Wu, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu, Jun Luo, Liling Zhang, Hongwei Xue, Qingyuan Zhang, Weiwei Wang, Chunxia Chen, Jifeng Feng, Jun Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7363–7369.
https://doi.org/10.1158/1078-0432.CCR-19-1680
Published: 13 December 2019
View articletitled, A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Open the PDF for A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis

Free
Vasily N. Aushev, Eunjee Lee, Jun Zhu, Kalpana Gopalakrishnan, Qian Li, Susan L. Teitelbaum, James Wetmur, Davide Degli Esposti, Hector Hernandez-Vargas, Zdenko Herceg, Humberto Parada, Regina M. Santella, Marilie D. Gammon, Jia Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (3): 581–591.
https://doi.org/10.1158/1078-0432.CCR-17-0996
Published: 31 January 2018
View articletitled, Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Open the PDF for Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis in another window
Includes: Supplementary data
Journal Articles

Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure

Free
Rihab Nasr, Valérie Lallemand-Breitenbach, Jun Zhu, Marie-Claude Guillemin, Hugues de Thé
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6321–6326.
https://doi.org/10.1158/1078-0432.CCR-09-0209
Published: 14 October 2009
View articletitled, Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure
Open the PDF for Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure in another window
Journal Articles

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

Free
Evangelia Razis, Panayotis Selviaridis, Stephanos Labropoulos, Jeremy L. Norris, Mei-Jun Zhu, David D. Song, Thea Kalebic, Michael Torrens, Anna Kalogera-Fountzila, George Karkavelas, Sofia Karanastasi, Jonathan A. Fletcher, George Fountzilas
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6258–6266.
https://doi.org/10.1158/1078-0432.CCR-08-1867
Published: 30 September 2009
View articletitled, Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Open the PDF for Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment in another window